Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03177889
Other study ID # GWJ-TCM-2017
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date December 31, 2021
Est. completion date December 31, 2023

Study information

Verified date February 2020
Source Guangzhou Institute of Respiratory Disease
Contact Wei-jie Guan, Ph.D.
Phone +86-13826042052
Email battery203@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Bronchiectasis is a chronic airway disease which confers significant healthcare burden, with limited therapeutic approaches. From the perspective of traditional Chinese medicine, congenital insufficiency of the lung, spleen and kidney, when coupled with external injury or mood impairment, may collectively contribute to bronchiectasis pathogenesis due to heat trapping in the phlems, congestion of wind evils and stagnation of blood. Here, the investigators will explore the Lung Dispersing, Turbid Descending and Gut Clearing Decoction (LTGD) which targets at expelling the wind evil in patients with bronchiectasis. The investigators sought to conduct a multicenter, randomized cross-over trial which investigates the efficacy and safety of LTGD on clinically stable bronchiectasis.


Description:

Bronchiectasis is a chronic airway disease which confers significant healthcare burden, with limited therapeutic approaches. From the perspective of traditional Chinese medicine, congenital insufficiency of the lung, spleen and kidney, when coupled with external injury or mood impairment, may collectively contribute to bronchiectasis pathogenesis due to heat trapping in the phlems, congestion of wind evils and stagnation of blood. Symptomatic treatment may be effective and safe for ameliorating respiratory symptoms and hindering disease progression of bronchiectasis. Here, the investigators have explored the Lung Dispersing, Turbid Descending and Gut Clearing Decoction (LTGD) which targets at expelling the wind evil in patients with bronchiectasis. The investigators sought to conduct a multicenter, randomized cross-over trial which investigates the efficacy and safety of LTGD on clinically stable bronchiectasis.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 80
Est. completion date December 31, 2023
Est. primary completion date August 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- aged between 18 and 75 years;

- remained clinically stable (respiratory symptoms and lung function parameters not exceeding normal daily variations) for 4 consecutive weeks;

- no acute upper respiratory tract infections within 4 weeks;

- 1 or more BEs within the previous 2 years

Exclusion Criteria:

- Other unstable concomitant systemic illnesses (i.e. coronary heart disease, recent cerebral stroke, severe uncontrolled hypertension, active gastric or duodenal ulcer, uncontrolled diabetes, malignancy, hepatic or renal dysfunction);

- Concomitant asthma, allergic bronchopulmonary aspergillosis, or active tuberculosis;

- Concomitant chronic obstructive pulmonary disease as the predominant diagnosis;

- Treatment with inhaled, oral or systemic antibiotics within 4 weeks;

- Type 2 respiratory failure needing oxygen therapy or non-invasive mechanical ventilation;

- Females during lactation or pregnancy;

- Poor understanding or failure to properly operate the instrument;

- Participation in other clinical trials within 3 months.

Study Design


Intervention

Combination Product:
Traditional Chinese Medicine (TCM)
Traditional Chinese Medicine plus oral mucolytics [ambroxol 30mg tid, or N-acetylcysteine 0.2g tid, serrapeptase 10mg tid, or carbocisteine 500mg tid]; Agastache rugosus 5g, Scutellaria baicalensis 10g, Radix Puerariae 10g, Acorus tatarinowii schott 10g, Fructus Liquidambaris 5g, gypsum 15 g, Rheum officinale 5 g, Folium sennae 5 g, Codonopsis pilosula 10g, Radix Salviae Miltiorrhizae 10g, Lignum millettiae 10 g, Liquiritia glycyrrhiza 10 g Optional formulae: bile arisaema 15g, polygala tenuifolia 15g, Mangnolia officinalis 10g, Fructus aurantii immaturus 10g; Magnetite 15-30g and reddle15-30g

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Guangzhou Institute of Respiratory Disease Guangdong Provincial Hospital of Traditional Chinese Medicine

References & Publications (11)

Guan WJ, Gao YH, Xu G, Lin ZY, Tang Y, Gu YY, Liu GH, Li HM, Chen RC, Zhong NS. Sputum matrix metalloproteinase-8 and -9 and tissue inhibitor of metalloproteinase-1 in bronchiectasis: clinical correlates and prognostic implications. Respirology. 2015 Oct;20(7):1073-81. doi: 10.1111/resp.12582. Epub 2015 Jun 30. — View Citation

Guan WJ, Gao YH, Xu G, Lin ZY, Tang Y, Li HM, Lin ZM, Zheng JP, Chen RC, Zhong NS. Impulse oscillometry in adults with bronchiectasis. Ann Am Thorac Soc. 2015 May;12(5):657-65. doi: 10.1513/AnnalsATS.201406-280OC. — View Citation

Guan WJ, Gao YH, Xu G, Lin ZY, Tang Y, Li HM, Lin ZM, Zheng JP, Chen RC, Zhong NS. Sputum bacteriology in steady-state bronchiectasis in Guangzhou, China. Int J Tuberc Lung Dis. 2015 May;19(5):610-9. doi: 10.5588/ijtld.14.0613. — View Citation

Horvath I, Loukides S, Wodehouse T, Kharitonov SA, Cole PJ, Barnes PJ. Increased levels of exhaled carbon monoxide in bronchiectasis: a new marker of oxidative stress. Thorax. 1998 Oct;53(10):867-70. — View Citation

Loukides S, Horvath I, Wodehouse T, Cole PJ, Barnes PJ. Elevated levels of expired breath hydrogen peroxide in bronchiectasis. Am J Respir Crit Care Med. 1998 Sep;158(3):991-4. — View Citation

Pasteur MC, Bilton D, Hill AT; British Thoracic Society Non-CF Bronchiectasis Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010 Jul;65(7):577. doi: 10.1136/thx.2010.142778. — View Citation

Quittner AL, O'Donnell AE, Salathe MA, Lewis SA, Li X, Montgomery AB, O'Riordan TG, Barker AF. Quality of Life Questionnaire-Bronchiectasis: final psychometric analyses and determination of minimal important difference scores. Thorax. 2015 Jan;70(1):12-20. doi: 10.1136/thoraxjnl-2014-205918. Epub 2014 Oct 16. — View Citation

Spinou A, Siegert RJ, Guan WJ, Patel AS, Gosker HR, Lee KK, Elston C, Loebinger MR, Wilson R, Garrod R, Birring SS. The development and validation of the Bronchiectasis Health Questionnaire. Eur Respir J. 2017 May 11;49(5). pii: 1601532. doi: 10.1183/13993003.01532-2016. Print 2017 May. — View Citation

Tsang KW, Chan K, Ho P, Zheng L, Ooi GC, Ho JC, Lam W. Sputum elastase in steady-state bronchiectasis. Chest. 2000 Feb;117(2):420-6. — View Citation

Zhang ZM, Ren PH, Wu ZJ, Zhang DP, Xie WJ. Personalized alternative therapy of intractable bronchiectasis-induced hemoptysis in a patient: syndrome differentiation and treatment according to individual physique category. J Thorac Dis. 2013 Jun;5(3):E115-7 — View Citation

Zheng J, Zhong N. Normative values of pulmonary function testing in Chinese adults. Chin Med J (Engl). 2002 Jan;115(1):50-4. — View Citation

* Note: There are 11 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Other changes in sputum hydrogen peroxide level at month 6 compared with baseline changes in sputum hydrogen peroxide level at month 6 compared with baseline 6 months
Other changes in sputum catalase activity at month 6 compared with baseline changes in sputum catalase activity at month 6 compared with baseline 6 months
Other changes in sputum total antioxidant capacity at month 6 compared with baseline changes in sputum total antioxidant capacity at month 6 compared with baseline 6 months
Other changes in airway resistance measured at 5 Hz at month 6 compared with baseline changes in airway resistance measured at 5 Hz at month 6 compared with baseline 6 months
Other changes in Quality-of-life-bronchiectasis questionnaire score at month 6 compared with baseline changes in Quality-of-life-bronchiectasis questionnaire score at month 6 compared with baseline 6 months
Other changes in sputum microbiota composition at month 6 compared with baseline changes in sputum microbiota composition at month 6 compared with baseline 6 months
Other Changes in AX at month 6 compared with baseline Changes in AX at month 6 compared with baseline 6 months
Other Changes in sputum superoxide dismutase activity at month 6 compared with baseline Changes in sputum superoxide dismutase activity at month 6 compared with baseline 6 months
Primary Changes in Bronchiectasis Health Questionnaire scores at month 6 compared with baseline Changes in Bronchiectasis Health Questionnaire scores at month 6 compared with baseline 6 months
Secondary the frequency of bronchiectasis exacerbation the frequency of bronchiectasis exacerbation 6 months
Secondary the time to the first bronchiectasis exacerbation the time to the first bronchiectasis exacerbation 6 months
Secondary changes in forced expiratory volume in one second at month 6 compared with baseline changes in forced expiratory volume in one second at month 6 compared with baseline 6 months
Secondary 24-hour sputum volume at month 6 compared with baseline 24-hour sputum volume at month 6 compared with baseline 6 months
Secondary changes in sputum purulence score at month 6 compared with baseline changes in sputum purulence score at month 6 compared with baseline 6 months
Secondary the proportion of patients isolated with Pseudomonas aeruginosa at month 6 compared with baseline the proportion of patients isolated with Pseudomonas aeruginosa at month 6 compared with baseline 6 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05559255 - Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI N/A
Completed NCT06238557 - Prospective Evaluation of Psychological Consequences and Impact on Long-term Quality of Life
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT05472935 - Asynchronous Mindfulness Based Stress Reduction to Reduce Burnout in Licensed Clinical Social Workers N/A
Recruiting NCT04444544 - Quality of Life and High-Risk Abdominal Cancer Surgery
Completed NCT04281953 - Impact on Quality of Life of Long-term Ototoxicity in Cancer Survivors
Recruiting NCT05546931 - Mobile Health Program for Rural Hypertension N/A
Active, not recruiting NCT04746664 - Effects of Nutrition Counselling on Old Age People's Nutritional Status and Quality of Life in Bahir Dar City, North West Ethiopia N/A
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Recruiting NCT04142827 - The Effect of Long Term Therapy With High Flow Humidification Compared to Usual Care in Patients With Bronchiectasis (BX) N/A
Active, not recruiting NCT05903638 - A Pilot RCT: the Impact of a Virtual MBSR Course on Women With Primary Infertility N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Completed NCT06216015 - Exercise Training and Kidney Transplantation N/A
Completed NCT03813420 - Sleep Quality of Physiotherapy Students Quality of Life and Physical Activity Level N/A
Recruiting NCT05550545 - Infant RSV Infections and Health-related Quality of Life of Families
Completed NCT05346588 - THRIVE Feasibility Trial Phase 3
Recruiting NCT05233020 - Robotic Versus Hybrid Assisted Ventral Hernia Repair N/A
Terminated NCT03304184 - The Role of Biodentine in Class V Dental Lesions on Oral Health Related Quality of Life Phase 3
Completed NCT05063305 - Probiotics, Immunity, Stress, and QofL N/A
Recruiting NCT05380856 - Sacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction N/A